BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21587131)

  • 1. Prognostic factors of pathologic stage IB non-small cell lung cancer.
    Yano M; Sasaki H; Moriyama S; Kawano O; Hikosaka Y; Fujii Y
    Ann Thorac Cardiovasc Surg; 2011; 17(1):58-62. PubMed ID: 21587131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy.
    Tsuchiya T; Akamine S; Muraoka M; Kamohara R; Tsuji K; Urabe S; Honda S; Yamasaki N
    Lung Cancer; 2007 Jun; 56(3):341-8. PubMed ID: 17350137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan.
    Eguchi K; Oyama T; Tajima A; Abiko T; Sawafuji M; Horio H; Hashizume T; Matsutani N; Kato R; Nakayama M; Kawamura M; Kobayashi K
    Lung Cancer; 2015 Jan; 87(1):53-8. PubMed ID: 25468199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
    Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
    BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of vascular invasion and standardization of its evaluation in stage I non-small cell lung cancer.
    Hamanaka R; Yokose T; Sakuma Y; Tsuboi M; Ito H; Nakayama H; Yamada K; Masuda R; Iwazaki M
    Diagn Pathol; 2015 Apr; 10():17. PubMed ID: 25884820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
    Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for elderly patients with non-small-cell lung cancer.
    Yamanashi K; Okumura N; Yamamoto Y; Takahashi A; Nakashima T; Matsuoka T; Kameyama K
    Asian Cardiovasc Thorac Ann; 2017 Jun; 25(5):371-377. PubMed ID: 28592139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
    Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of uncertain parietal pleural invasion at adhesion sites in non-small cell lung cancer patients.
    Mikubo M; Nakashima H; Naito M; Matsui Y; Shiomi K; Jiang SX; Satoh Y
    Lung Cancer; 2017 Jun; 108():103-108. PubMed ID: 28625620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
    Xie J; Zhang X; Hu S; Peng WD; Xu B; Li Y; Zhang SJ; Li Q; Li C
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2231-2239. PubMed ID: 32533405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of lymphovascular invasion compared with that of visceral pleural invasion in patients with pN0 non-small-cell lung cancer and a tumor diameter of 2 cm or smaller.
    Tao H; Hayashi T; Sano F; Takahagi A; Tanaka T; Matsuda E; Okabe K
    J Surg Res; 2013 Nov; 185(1):250-4. PubMed ID: 23830361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
    Yun HR; Kim HC; Yun SH; Lee WY
    Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for disease-free survival in pT2N0 non-small cell lung cancer.
    Park I; Chung KY; Kim KD; Kim DJ
    Asian Cardiovasc Thorac Ann; 2006 Apr; 14(2):139-44. PubMed ID: 16551822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive intraoperative pleural lavage cytology is a predictive marker of disease recurrence in stage I lung adenocarcinoma.
    Yanagawa N; Shiono S; Abiko M; Abe M; Watanabe K; Watanabe I; Uematsu M; Ogata SY; Sato T; Tamura G
    Interact Cardiovasc Thorac Surg; 2014 May; 18(5):621-5. PubMed ID: 24532312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion.
    Wang S; Xu J; Wang R; Qian F; Yang W; Qiao R; Zhang B; Qian J; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Nov; 156(5):2006-2015.e2. PubMed ID: 30104070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage IB nonsmall cell lung cancers: are they all the same?
    Jones DR; Daniel TM; Denlinger CE; Rundall BK; Smolkin ME; Wick MR
    Ann Thorac Surg; 2006 Jun; 81(6):1958-62; discussion 1962. PubMed ID: 16731113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
    Kato H; Ichinose Y; Ohta M; Hata E; Tsubota N; Tada H; Watanabe Y; Wada H; Tsuboi M; Hamajima N; Ohta M;
    N Engl J Med; 2004 Apr; 350(17):1713-21. PubMed ID: 15102997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
    Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
    Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for tumor recurrence in patients with early-stage (stage I and II) non-small cell lung cancer: patient selection criteria for adjuvant chemotherapy according to the seventh edition TNM classification.
    Maeda R; Yoshida J; Ishii G; Hishida T; Nishimura M; Nagai K
    Chest; 2011 Dec; 140(6):1494-1502. PubMed ID: 21622548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.